Back to Search
Start Over
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
- Source :
-
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2020 Jun 23; Vol. 64 (7). Date of Electronic Publication: 2020 Jun 23 (Print Publication: 2020). - Publication Year :
- 2020
-
Abstract
- Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC <subscript>50</subscript> s), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects.<br /> (Copyright © 2020 American Society for Microbiology.)
- Subjects :
- Animals
Anti-Inflammatory Agents pharmacology
Antiviral Agents pharmacology
COVID-19
Cell Line
Chlorocebus aethiops
Drug Evaluation, Preclinical methods
Humans
Pandemics
SARS-CoV-2
Vero Cells
Betacoronavirus drug effects
Coronavirus Infections drug therapy
Drug Repositioning
Niclosamide pharmacology
Pneumonia, Viral drug therapy
Pregnenediones pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1098-6596
- Volume :
- 64
- Issue :
- 7
- Database :
- MEDLINE
- Journal :
- Antimicrobial agents and chemotherapy
- Publication Type :
- Academic Journal
- Accession number :
- 32366720
- Full Text :
- https://doi.org/10.1128/AAC.00819-20